/

Johnson & Johnson

JNJ US

JNJ USJohnson & Johnson

United States Composite

148.53

USD

-1.03

(-0.69%)

13.77EPS Dil.

10.70P/E

357.52BMarket Cap

3.13%Div. Yield

Next Earnings

April 16

Ex-Dividend Date

February 16

Dividend Date

March 5

Held by Insiders

0.09%

Held by Institutions

71.28%

Short % of Float

0.62%

YTD Yield

-9.72%

3Y Yield

-9.91%

5Y Yield

6.78%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

11,701

3,870

3,451

LT Borrowings

33,901

26,051

25,881

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

2,598

2,407

Market Capitalization

430,045

374,918

377,285

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

60,567

53,703

53,495

Cash, Cash Equivalents & STI

28,505

23,511

22,927

Accounts Receivable, Net

16,777

14,798

14,873

Inventories

12,888

11,198

11,181

Total Current Liabilities

54,170

44,370

46,282

Payables & Accruals

39,407

37,163

38,838

ST Debt

11,701

3,870

3,451

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

1.88%

0.92%

6.46%

Net Income, GAAP

112.42%

23.98%

95.94%

Free Cash Flow

2.82%

-0.57%

3.45%

Total Cash Common Dividend

4.93%

4.41%

0.75%

Total Equity

-0.39%

3.24%

-10.46%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

22,321

23,312

23,338

24,804

78,740

2022

23,426

24,020

19,996

23,706

79,990

2023

24,746

25,530

21,351

21,395

85,159

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

2.35

2.38

1.39

1.80

7.93

2022

1.96

1.83

1.70

1.35

6.83

2023

-0.03

1.98

10.32

1.68

13.88

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

1.01

1.06

4.19

2022

1.06

1.13

4.45

2023

1.13

1.19

1.14

1.19

4.65

Company Description

CEO: Mr. Joaquin Duato
Full Time Employees: 131,900
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: One Johnson & Johnson Plaza New Brunswick NJ United States 08933
IPO Date: Jan 2, 1962
CIK: 0000200406
Website: www.jnj.com
Business: Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Company News

Zacks
22 days ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Yahoo
23 days ago
Johnson & Johnson (JNJ) Stock Moves -0.03%: What You Should Know
Zacks
23 days ago
Johnson & Johnson (JNJ) Stock Moves -0.03%: What You Should Know
Reuters
23 days ago
Investors hope GE spinoff will defy poor track record of breakups
Reuters
23 days ago
US takes next step in Medicare drug price negotiations with pharma companies
Zacks
23 days ago
AI ETFs: Q1 of 2024 Update
Reuters
24 days ago
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Yahoo
a month ago
25 Things Every Dividend Investor Should Know
CNBC
a month ago
Microsoft, Salesforce woo skeptical CFOs on new generative AI tool spending
Yahoo
a month ago
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Zacks
a month ago
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
FOOL
a month ago
Why Shockwave Medical Stock Rallied as Much as 18% Higher This Week
Yahoo
a month ago
Declining Stock and Decent Financials: Is The Market Wrong About Johnson & Johnson (NYSE:JNJ)?
Bloomberg
a month ago
Convincing Religious Groups to Get Measles Shots
Zacks
a month ago
Shockwave Medical (SWAV) Up on Potential Acquisition Rumors
Zacks
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Bloomberg
a month ago
Kodak’s Pension Windfall Points to a $137 Billion Opportunity
Bloomberg
a month ago
J&J to Pay $75 Million to Settle Mississippi’s Baby Powder Suit
Zacks
a month ago
4 Best ETF Areas of Q1
Yahoo
a month ago
UPDATE 3-J&J can contest evidence linking its talc to cancer, US judge rules

Company News

Zacks
22 days ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Yahoo
23 days ago
Johnson & Johnson (JNJ) Stock Moves -0.03%: What You Should Know
Zacks
23 days ago
Johnson & Johnson (JNJ) Stock Moves -0.03%: What You Should Know
Reuters
23 days ago
Investors hope GE spinoff will defy poor track record of breakups
Reuters
23 days ago
US takes next step in Medicare drug price negotiations with pharma companies
Zacks
23 days ago
AI ETFs: Q1 of 2024 Update
Reuters
24 days ago
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Yahoo
a month ago
25 Things Every Dividend Investor Should Know
CNBC
a month ago
Microsoft, Salesforce woo skeptical CFOs on new generative AI tool spending
Yahoo
a month ago
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Zacks
a month ago
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
FOOL
a month ago
Why Shockwave Medical Stock Rallied as Much as 18% Higher This Week
Yahoo
a month ago
Declining Stock and Decent Financials: Is The Market Wrong About Johnson & Johnson (NYSE:JNJ)?
Bloomberg
a month ago
Convincing Religious Groups to Get Measles Shots
Zacks
a month ago
Shockwave Medical (SWAV) Up on Potential Acquisition Rumors
Zacks
a month ago
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Bloomberg
a month ago
Kodak’s Pension Windfall Points to a $137 Billion Opportunity
Bloomberg
a month ago
J&J to Pay $75 Million to Settle Mississippi’s Baby Powder Suit
Zacks
a month ago
4 Best ETF Areas of Q1
Yahoo
a month ago
UPDATE 3-J&J can contest evidence linking its talc to cancer, US judge rules

Company Description

CEO: Mr. Joaquin Duato
Full Time Employees: 131,900
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: One Johnson & Johnson Plaza New Brunswick NJ United States 08933
IPO Date: Jan 2, 1962
CIK: 0000200406
Website: www.jnj.com
Business: Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.